<unk>  is a Immunological Agent that is FDA approved for the treatment of INFERGEN is indicated for the treatment of chronic HCV infection in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies and/or the presence of HCV RNA. Other causes of hepatitis, such as viral hepatitis B or autoimmune hepatitis, should be ruled out prior to initiation of therapy with INFERGEN. In some patients with chronic HCV infection, INFERGEN normalizes serum ALT, reduces serum HCV RNA concentrations to undetectable quantities (< 100 copies/mL), and improves liver histology..   Common adverse reactions include Injection site reactions, fatigue, fever, rigors, body pain.
Interferon alfacon-1
Interferon Alfa-n3
Interferon alfa-2b
Peginterferon Beta-1a
Interferon alfa-2a
Interferon type I
Interferon beta-1b
Aldesleukin